// App-Quantinova.ai

PB0921 : Efficacy and Target Joint Resolution with Pharmacokinetic-Guided Rurioctocog Alfa Pegol Prophylaxis Targeting Two Factor VIII trough Levels in Patients with Severe Hemophilia A: Post-Hoc Analysis of the Phase 3 PROPEL Trial

Researchers

Presenter

  • P. Collins

Principal Investigators

  • J. Windyga

  • M. Escobar

  • H.M. Ibrahim

  • J.C.M. Lam

  • S.D. Tangada

  • W. Engl

  • I. Honauer

  • A. Fernandez

  • H.-Y. Lee

  • R. Klamroth

  • C. Escuriola-Ettingshausen

Medical Centers

  • Cardiff University School of Medicine, Cardiff, United Kingdom

  • Institute of Hematology and Transfusion Medicine, Department of Hemostasis Disorders and Internal Medicine, Warsaw, Poland

  • University of Texas Health Science Center at Houston - Medical School, Houston, Texas, United States

  • Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

  • K.K. Women's and Children's Hospital, Singapore, Singapore

  • Baxalta US Inc., a Takeda Company, Cambridge, United States

  • Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria

  • Shire International GmbH, a Takeda company, Zug, Switzerland

  • Vivantes Klinikum Am Friedrichshain, Berlin, Germany

  • Haemophilie Zentrum Rhein Main, Morfelden-Walldorf, Germany

Locations

  • United Kingdom

  • Poland

  • United States

  • Malaysia

  • Singapore

  • Austria

  • Switzerland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • rurioctocog alfa

  • FVIII

  • Propel

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

Phase

  • III

Study Id's

  • NCT02585960

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved